Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease

Prostate

Volumn 43, Issue 4, 2000, Pages 248-254

  Thompson, Timothy C ^a,b   Timme, Terry L ^a,b   Park, Sang Hee ^a   Yang, Guang ^a   Ren, Chengzhen ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Caveolin 1; Chemoprevention; Gene therapy; Oncogenes; Prostate cancer

Indexed keywords

RETINOID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; DISEASE MODEL; GENE THERAPY; GROWTH REGULATION; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE DISEASE;

ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; MALE; MICE; ONCOGENES; PROSTATIC DISEASES; PROSTATIC NEOPLASMS;

EID: 0034212739     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20000601)43:4<248::AID-PROS3>3.0.CO;2-P     Document Type: Article

References (47)

1. Thompson TC. Mouse prostate reconstitution: an in vivo transgenic gland model system. Urol Oncol 1996;2:117-119.
2. Cunha GR. Epithelio-mesenchymal interactions in primordial gland structures which become responsive to androgenic stimulation. Anat Rec 1972;172:179-195.
3. Cunha GR, Chung LW, Shannon JM, Taguchi O, Fujii H. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Recent Prog Horm Res 1983;39:559-598.
4. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56:917-930.
5. Timme TL, Yang G, Rogers E, Kadmon D, Morganstern JP, Park SH, Thompson TC. Retroviral transduction of transforming growth factor-betal induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab Invest 1996;74:747-760.
6. Yang G, Timme TL, Park SH, Thompson TC. Transforming growth factor beta 1 transduced mouse prostate reconstitutions: 1. Induction of neuronal phenotypes. Prostate 1997;33:151-156.
7. Yang G, Timme TL, Park SH, Wu X, Wyllie MG, Thompson TC. Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. Prostate 1997;33:157-163.
8. Carter BS, Epstein JI, Isaacs WB. ras gene mutations in human prostate cancer. Cancer Res 1990;50:6830-6832.
9. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 1992;52: 5991-5996.
10. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-284.
11. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, Jenkins RB. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999;91:1574-80.
12. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 1995;52:403-413.
13. Thompson TC. Growth factors and oncogenes in prostate cancer. Cancer Cells 1990;2:345-354.
14. Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, Thompson TC. Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. Mol Endocrinol 1991;5:503-513.
15. Sehgal I, Baley PA, Thompson TC. Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 1996;56:3359-3365.
16. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem [Suppl] 1992;16:54-61.
17. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol 1993;24:4-9.
18. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 1995;73:628-635.
19. Thompson TC, Timme TL, Kadmon D, Park SH, Egawa S, Yoshida K. Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog 1993;7:165-179.
20. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transgenic models for the study of prostate cancer. Cancer 1993;71:1165-1171.
21. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 1994; 25:797-801.
22. Aihara M, Scardino PT, Truong LD, Wheeler TM, Goad JR, Yang G, Thompson TC. The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer 1995;75:522-529.
23. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, Yang G. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 1995;10:869-879.
24. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-1669.
25. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993;53:3369-3373.
26. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1995;1:1111-1118.
27. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, Roy-Burman P. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995;147: 92-101.
28. Yang G, Stapleton AM, Wheeler TM, Truong LD, Timme TL, Scardino PT, Thompson TC. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 1996;2:399-401.
29. Stapleton AM, Timme TL, Gousse AE, Li QF, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 1997;3: 1389-1397.
30. Varmus H. Retroviruses. Science 1988;240:1427-1435.
31. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE, Crissman JD. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 1994;54:3273-3277.
32. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, Jenkins RB. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995;55:5408-5414.
33. Hall SJ, Thompson TC. Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs. metastasis-derived mouse prostate cancer cell lines. Clin Exp Metastasis 1997;15:630-638.
34. Bangma CH, Nasu Y, Ren C, Thompson TC. Metastasis-related genes in prostate cancer. Semin Oncol 1999;26:422-427.
35. Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res 1993;53:4461-4465.
36. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW, Thompson TC. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995;55:5151-5155.
37. Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SL, Thompson TC. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 1996;7:515-523.
38. Hall SJ, Mutchnik SE, Chen SH, Woo SL, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 1997;70:183-187.
39. Hall SJ, Mutchnik SE, Yang G, Timme TL, Nasu Y, Bangma CH, Woo SL, Shaker M, Thompson TC. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther 1999;6:54-63.
40. Hall SJ, Sanford MA, Atkinson G, Chen SH. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res 1998;58:3221-3225.
41. Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J, McCurdy MA, Shimura S, Yang G, Timme TL, Thompson TC. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and preestablished lung metastases in an orthotopic model. Gene Ther 1999;6:338-349.
42. Kawakita M, Rao GS, Ritchey JK, Ornstein DK, Hudson MA, Tartaglia J, Paoletti E, Humphrey PA, Harmon TJ, Ratliff TL. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst 1997; 89:428-436.
43. Ren C, Yang G, Timme TL, Wheeler TM, Thompson TC. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res 1998;58:1285-1290.
44. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998;4:1873-1880.
45. Parton RG. Caveolae and caveolins. Curr Opin Cell Biol 1996; 8:542-548.
46. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, Thompson TC. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 1998;4:1062-1064.
47. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 1999;59:5719-5723.